Deriving Immune Modulating Drugs from Viruses—A New Class of Biologics
Authors:
- Jordan R. YaronJordan R. Yaron
- Liqiang ZhangLiqiang Zhang
- Qiuyun GuoQGQiuyun Guo
- Michelle BurginMBMichelle Burgin
- Lauren N. SchutzLSLauren N. Schutz
- Enkidia AwoEAEnkidia Awo
- Lyn WiseLWLyn Wise
- Kurt L. KrauseKKKurt L. Krause
- Cristhian J. IldefonsoCICristhian J. Ildefonso
- Jacek M. KwiecienJKJacek M. Kwiecien
- Michael JubyMJMichael Juby
Open Access
- 31 March 2020
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (4) , 972
Abstract
Viruses are widely used as a platform for the production of therapeutics. Vaccines containing live, dead and components of viruses, gene therapy vectors and oncolytic viruses are key examples of clinically-approved therapeutic uses for viruses. Despite this, the use of virus-derived proteins as natural sources for immune modulators remains in the early stages of development. Viruses have evolved complex, highly effective approaches for immune evasion. Originally developed for protection against host immune responses, viral immune-modulating proteins are extraordinarily potent, often functioning at picomolar concentrations. These complex viral intracellular parasites have “performed the R&D”, developing highly effective immune evasive strategies over millions of years. These proteins provide a new and natural source for immune-modulating therapeutics, similar in many ways to penicillin being developed from mold or streptokinase from bacteria. Virus-derived serine proteinase inhibitors (serpins), chemokine modulating proteins, complement control, inflammasome inhibition, growth factors (e.g., viral vascular endothelial growth factor) and cytokine mimics (e.g., viral interleukin 10) and/or inhibitors (e.g., tumor necrosis factor) have now been identified that target central immunological response pathways. We review here current development of virus-derived immune-modulating biologics with efficacy demonstrated in pre-clinical or clinical studies, focusing on pox and herpesviruses-derived immune-modulating therapeutics.Keywords
Funding Information
- National Institutes of Health (1R01AI100987-01A1, 1RC1HL100202)
- American Heart Association (17GRNT33460327)
- University of Florida Foundation (00115070)
- Biodesign Institute at Arizona State University (Start-Up)
This publication has 202 references indexed in Scilit:
- Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse modelsBMC Immunology, 2013
- Delayed activation of caspase-independent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmAAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Attenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmDMucosal Immunology, 2010
- Effective Blockage of Both the Extrinsic and Intrinsic Pathways of Apoptosis in Mice by TAT-crmAJournal of Biological Chemistry, 2010
- Expression of the Chemokine Binding Protein M3 Promotes Marked Changes in the Accumulation of Specific Leukocytes Subsets Within the IntestineGastroenterology, 2009
- Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organizationBlood, 2008
- Monkeypox virus and insights into its immunomodulatory proteinsImmunological Reviews, 2008
- Monkeypox virus viral chemokine inhibitor (MPV vCCI), a potent inhibitor of rhesus macrophage inflammatory protein-1Cytokine, 2008
- Regulation of scar formation by vascular endothelial growth factorLaboratory Investigation, 2008
- A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virusProceedings of the National Academy of Sciences, 2006